Abstract: The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

Abstract: The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

Abstract: A system for determining an analyte (for example glucose) in a bodily fluid sample (e.g., a whole blood sample) includes a meter and at least one analytical test strip configured for the application of the bodily fluid sample thereon and for insertion into the meter for subsequent determination of the analyte. Furthermore, the meter includes a graphics-based step-by-step tutorial module with a user interface, a microprocessor unit and a memory unit storing a step-by-step tutorial that includes graphics-based images depicting use of the system. In addition, the user interface, microprocessor unit and memory unit are operatively linked and configured for sequential display of the graphics-based images of the step-by-step tutorial to the user via, for example, a display screen.

Abstract: A method for tutoring a user during use of a system for determining an analyte (for example, glucose) in a bodily fluid sample (e.g., a whole blood sample) include activating a system for determining an analyte in a bodily fluid sample. The system that is activated includes a meter and at least one analytical test strip configured for the application of the bodily fluid sample thereon and for insertion into the meter for subsequent determination of the analyte. Furthermore, the meter includes a graphics-based step-by-step tutorial module with a user interface, a microprocessor unit and a memory unit storing a step-by-step tutorial that includes graphics-based images depicting use of the system. In addition, the user interface, microprocessor unit and memory unit are operatively linked and configured for sequential display of the graphics-based images of the step-by-step tutorial to the user via, for example, a display screen.

Abstract: The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

Abstract: The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

Abstract: The invention relates to methods of treating a blood disorder in a mammmal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

Abstract: A thermal-dye-bleach construction comprising a dye in association with a thermal dye-bleaching agent of general formula I: ##STR1## wherein: each of R.sup.a and R.sup.b are individually selected from: hydrogen, an alkyl group, an alkenyl group, a cycloalkyl group, an aralkyl group, an aryl group, and a heterocyclic group, and preferably, both R.sup.a and R.sup.b represent hydrogen;p is one or two, and when p is one, Z is a monovalent group selected from: an akyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, and a heterocyclic group, and when p is two, Z is a divalent group selected from: an alkylene group, an arylene group, an alkenylene group, an alkynylene group, an aralkylene group, a cycloalkene group, and a heterocyclic group; and,M.sup.+ is a cation which will not react with a carbanion generated from the thermal-carbanion-generating agent in such manner as to render the carbanion ineffective as a bleaching agent for the dye.

Abstract: A thermal-dye-bleach construction comprising a dye in association with a thermal dye-bleaching agent of general formula I: ##STR1## wherein: each of R.sup.a and R.sup.b are individually selected from: hydrogen, an alkyl group, an alkenyl group, a cycloalkyl group, an aralkyl group, an aryl group, and a heterocyclic group, and preferably, both R.sup.a and R.sup.b represent hydrogen;p is one or two, and when p is one, Z is a monovalent group selected from: an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, and a heterocyclic group, and when p is two, Z is a divalent group selected from: an alkylene group, an arylene group, an alkenylene group, an alkynylene group, an aralkylene group, a cycloalkene group, and a heterocyclic group; and,M.sup.+ is cation which will not react with acarbanion generated from the thermal-carbanion-generating agent in such manner as to render the carbanion ineffective as a bleaching agent for the dye.

Abstract: A thermal-dye-bleach construction comprising a polymethine dye having a nucleus of general formula I: ##STR1## in association with a thermal-carbanion-generating agent having the general formula: ##STR2## wherein the substituents are as defined in the specification and claims.